Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Rare Cancer Orphan Drug Clinical Trials Insight 2028

Published

on

Singapore, May 19, 2022 (GLOBE NEWSWIRE) — Global Orphan Drugs Market & Clinical Trials Insight Report 2028 Highlights:

  • Clinical Insight On More Than 600 Marketed Orphan Drugs
  • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials
  • Orphan Designated Drug Clinical Status by Indication & Country
  • Global Market Opportunity More Than USD 350 Billion
  • Market Exclusivity & Patent Protection Criteria for Orphan Drugs
  • Global & Regional Orphan Drug Market Sales Opportunity
  • Orphan Drug Reimbursement Policy
  • Orphan Clinical Pipeline Overview Company, Drug Class, Formulation, Indication, Region, Priority Status, Patient Segment, Phase

Download Report Sample:

https://www.kuickresearch.com/ccformF.php?t=1643976472

Over the past few years, it is observed that the incidence rate of rare disorders is increasing rapidly and hence the demand of novel drugs targeting these conditions is rising year by year. Orphan drugs are a special category of drugs, which are intended to treat rare disease. Till date, about 500 drugs have been granted orphan designation by regulatory bodies and about 200 of them are currently available in the global market. Although the target population size is small, these drugs have shown robust sales in the market which indicates promising future of orphan drug in the global market.

One of the major factor responsible for rapid increase in market size of orphan drug is that the orphan drugs have a market exclusivity of 7 years and hence provides high cost saving for the development of niche drugs. The 1983 orphan drug act also encourages the pharmaceutical giants for developing orphan drugs and provides several benefits including tax and incentive savings. In additrion to this, the orphan drugs require less amount of funds for advertising and marketing of drug as the target population is small as well as the price of orphan drug is also less as compared to niche drugs. All these benefits of orphan drugs are indicating the huge market potential of this segment which attract pharmaceutical giants to invest in this segment.

The global orphan drug market is highly consolidated and consists of several major key players including Novartis, Pfizer, Merck, Sanofi, Amgen, Biogen, Takeda Pharmaceutical, and several others. Rapid launch of new products is one of the major factors which are adopted by key players in the market. For instance in 2022, EDI-301 developed by Edita Medicine has received orphan drug designation by US FDA for the treatment of beta thalassemia. EDIT-301 is an experimental gene editing therapy which consists of CD34+ hematopoietic stem and progenitor cells obtained from patients and are edited at the gamma globin gene (HBG1 and HBG2) promoters by a AsCas12a nuclease and is present in phase-I/II clinical trials.    

One of the biggest challenges faced by the physicain for the management of orphan disease is related to the difficulty in diagnosis and medical condition of patients. This is mainly due to lack of investigation of the disease and hence physician try to provide symptomatic relife to the patient without targeting the major cause.   For overcoming this challenge, researchers are employing several advanced technologies. The entrance of artificial intelligence can act as gamechanger as it can help the physician to understand the patient’s condition as well as to develop novel drug candidate in minimum time period.

It is believed that several rare genetic diseases are associated with the appearance or gradual development of distinctive facial appearances in affected individuals. FDNA has developed Face2Gene, which is a novel technology that analyzes facial photos to identify facial morphology associated with rare diseases. This is a free tool used by hundreds of geneticists worldwide and the technology converts facial photos into a de-identified mathematical algorithm that describes the characteristics of each facial feature. FDNA is collecting data from images of individuals with confirmed diagnosis of many different genetic diseases to further improve this technology. These rising trends in the market will boost the growth of market during the forecast period.

As per our report findings, the global orphan drug market is expected to surpass US$ 350 Billion by 2028. The increase in prevalence of cancers and other rare genetic disorders is one of the key factors driving the growth of orphan drugs market The market is also driven by the increasing awareness among the population regarding the benefits of orphan drugs. In addition, implementations of new laws and rising government initiatives are expected to boost the growth of market in coming few years.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

University medical centers in Germany choose Sectra’s radiology solution to streamline workflows and shorten lead times for patients

Published

on

university-medical-centers-in-germany-choose-sectra’s-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients

LINKÖPING, Sweden, April 23, 2024 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany—Universitätsklinikum Tübingen and Universitätsmedizin Göttingen. By implementing Sectra’s radiology solution, the hospitals aim to improve and streamline radiology workflows with Sectra’s tools for enhanced reporting efficiency, in turn speeding up diagnostics.

“When choosing a vendor, we wanted one that could provide us with a stable and fast system. We also wanted one facilitating collaboration among our radiologists. That way we can streamline our radiology workflows and in turn shorten lead times for patients as well as reduce the ever increasing workload for radiologists,” says Dr. Babak Panahi, Managing Senior Physician and Head of CT and CT Intervention, Universitätsmedizin Göttingen.
Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in Germany managing 300,000 and 600,000 radiology exams a year. The two separate contracts for Sectra’s radiology solution were both signed during the third quarter of Sectra’s 2023/2024 fiscal year.
“Radiologists are under a lot of pressure as they are challenged to handle more images and more complex cases with less resources. Having a solution designed to streamline radiology workflows, facilitating reading and reporting of images, is therefore paramount. I am happy and excited to support Universitätsmedizin Göttingen and Universitätsklinikum Tübingen on their journey towards efficient radiology diagnostics,” says Guido Bötticher, Managing Director, Sectra DACH.
The radiology module is part of Sectra’s enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in ‘Best in KLAS’.
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2022/2023 fiscal year totaled SEK 2,351 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra  AB, 46 (0) 705 23 52 27Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/university-medical-centers-in-germany-choose-sectra-s-radiology-solution-to-streamline-workflows-and,c3965089
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-radiology-solution,c3291783
Sectra’s radiology solution
 

View original content:https://www.prnewswire.co.uk/news-releases/university-medical-centers-in-germany-choose-sectras-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients-302124211.html

Continue Reading

Artificial Intelligence

New CPS Protection Platform: TXOne Networks Unveils SageOne at GISec Global

Published

on

new-cps-protection-platform:-txone-networks-unveils-sageone-at-gisec-global

TAIPEI, April 23, 2024 /PRNewswire/ — TXOne Networks, a frontrunner in the realm of cyber-physical systems (CPS) security, is set to unveil its groundbreaking CPS security platform, SageOne, at the highly anticipated GISec Global from April 23rd to 25th, 2024. Attendees can find TXOne Networks showcasing SageOne at stand B99 in hall 5. This innovative platform consolidates all CPS security products onto a single, central management platform, promising streamlined operations and optimized threat detection capabilities.

SageOne, aptly named “Wise Man Number One,” serves as a comprehensive management console providing a holistic view of the CPS attack surface within operational technology (OT) environments. By enabling centralized control of TXOne’s three core product lines – Stellar for endpoint protection, Element for security inspection, and Edge for network defense – SageOne facilitates integrated OT security throughout the lifecycle of protected assets, ensuring robust threat detection and response mechanisms.
Key features of SageOne include:
CPS Attack Surface Management: Prioritizing operational security by offering clear visibility into the overall security posture of OT environments, SageOne identifies security focal points, illuminating asset information and security controls.Integrated Lifecycle Protection: Through centralized management, SageOne simplifies cybersecurity governance and fosters collaborative defense. It serves as an abstraction layer, facilitating contextualization and consolidation of data across multiple products, offering tailored, task-oriented consoles for executives, security personnel, and plant leaders.CPS Threat Detection & Response: SageOne aggregates security insights from various solutions to scout for potential risks, enabling early caution and response to both known and unknown threats.SageOne’s foundation rests upon advanced components, including Threat Intelligence, Behavior-Based AI Analytics Engines, Compliance Framework, Data Visualizer, and Ecosystem Integrator, ensuring comprehensive protection and seamless integration of different tools and technologies.
With its focus on analyzing unexpected behavior and unknown threats, SageOne enables the identification of suspicious events through cross-telemetry analysis within the OT-native XDR engine. This amalgamation of advanced technologies and user-friendly interface ensures the protection of critical infrastructures.
For rapid threat response, SageOne issues early warnings of suspicious behavior and orchestrates cross-telemetry analysis for CPS Threat Detection & Response. Integrated Lifecycle Protection ensures the security of devices and systems throughout their service life, contributing to great cost efficiency.
TXOne Networks reaffirms its commitment to CPS security and continuous advancement in OT security through SageOne. Visit TXOne Networks at the GISec Global from April 23rd to 25th, 2024, at stand B99 in hall 5.
For further updates and information, follow TXOne Networks on the blog, Twitter, and LinkedIn.
About TXOne Networks:
TXOne Networks provides OT security products ensuring reliability and security in industrial control systems and operational technology environments through the OT Zero Trust methodology. Collaborating with leading industrial manufacturers and critical infrastructure operators, TXOne Networks offers practical and business-friendly approaches to OT defense. Its network and endpoint-based products secure OT networks and mission-critical devices in real-time with high security depth.
Website: www.txone.com 
Photo – https://mma.prnewswire.com/media/2389611/SageOne_header_3.jpg

View original content:https://www.prnewswire.co.uk/news-releases/new-cps-protection-platform-txone-networks-unveils-sageone-at-gisec-global-302119386.html

Continue Reading

Artificial Intelligence

Imparta Launches World’s First Sales Methodology-Aware AI

Published

on

imparta-launches-world’s-first-sales-methodology-aware-ai

LONDON, April 23, 2024 /PRNewswire/ — Imparta Ltd, a global leader in performance improvement for customer-facing teams, has announced the release of i-Coach AI, the world’s first sales methodology-aware AI.

Over the past 18 months, AI has reshaped many industries and professions, with sales being no exception. Yet, generic LLMs such as ChatGPT are poor at coaching, and at selling. Even data-driven AI insights are only as good as the qualitative frameworks that underpin their observations.
i-Coach AI is the first expert Sales AI Coach that follows a proven, structured coaching process, and is fluent in all aspects of sales, account management, negotiation, customer success, commercial and business acumen, sales management and sales leadership. It is powered by Imparta’s award-winning, research-based Agile 3D methodology and complete, modular skills library.
Richard Barkey, Founder and CEO of Imparta, said “GenAI is one of the few truly transformative technologies in our lifetimes, and one that no sales organisation can ignore. We are genuinely excited to introduce i-Coach AI, an enterprise-grade coaching tool for salespeople, managers and leaders. I’m not exaggerating when I say that I’m using i-Coach AI myself, to think through strategies around specific clients, and indeed for the whole business. This tool is designed to integrate seamlessly across various sales ecosystems and tech stacks, and provides targeted, IP-aware coaching and practice simulations of customer conversations, at multiple points of need.”
As part of the launch, Imparta will host a webinar on April 23rd and May 2nd, hosted by Richard Barkey, titled ‘Leveraging Sales Methodology-Aware AI at Scale in the Enterprise’. Click here to learn more.
During this webinar, Richard will announce details of i-Coach AI and Imparta’s upcoming course for sales teams: Leveraging AI for Sales. He will also set out a range of essential use cases that we are rolling out across Imparta’s agile sales ecosystem and across the tech stack.
About Imparta
Imparta is a global leader in performance improvement for Sales, CX and Leadership. Our modular ecosystem includes three elements, developed through 25 years of research and experience with leading global organisations: Agile Sales Methodology, Agile Change Process and AI Sales Technology.
Whether you need to plug a gap in your existing training, provide self-paced learning, or build an entire Sales, CX or Leadership Academy, get in touch at [email protected].
Website: www.imparta.com
Photo: https://mma.prnewswire.com/media/2392278/i_Coach_Imparta_Ltd.jpg
Contact details: Adam [email protected] Tel: +44 (0) 20 7610 8800

View original content:https://www.prnewswire.co.uk/news-releases/imparta-launches-worlds-first-sales-methodology-aware-ai-302123771.html

Continue Reading

Trending